Chart pattern: Double Bottom (weekly)
▲ Broken out
Broke on Oct 30, 2026 · measured target $20.90 (+5%). Details →
Nov 5, 7:45 AM ET
Viatris reported third-quarter 2026 total revenues of $3.75 billion and a U.S. GAAP net loss of $325 million alongside adjusted EBITDA of $1.20 billion. The company raised its full-year 2026 financial guidance midpoints across all metrics and announced plans to acquire Pacira BioSciences for $1.65 billion. Shareholders also benefited from $717 million in year-to-date capital returns, including share repurchases.
- Total revenues were $3.75 billion in the third quarter of 2026, matching the prior-year period.
- U.S. GAAP net loss widened to $325 million from $128 million in the third quarter of 2025.
- Adjusted EBITDA reached $1.20 billion, up 4% on a reported basis from the prior-year period.
- The company agreed to acquire Pacira BioSciences for $36.50 per share in cash, representing an equity value of $1.65 billion.
Read the filing on SEC.gov ↗
Oct 8, 8:38 AM ET
Viatris signed a merger agreement on October 8, 2026 to acquire Pacira BioSciences through a cash tender offer at $36.50 per share, an aggregate equity value of $1.65 billion. Viatris said it expects to fund the deal primarily from excess cash, with the rest from short-term borrowings, and expects it to be immediately accretive to its financial guidance metrics and to close by the end of 2026. The deal is a large acquisition that would add Pacira's marketed EXPAREL and ZILRETTA products to Viatris.
- Offer price of $36.50 per share in cash; aggregate equity value of $1.65 billion per the joint press release.
- Pacira generated approximately $746 million in total revenue and $177 million in adjusted EBITDA for the twelve months ended June 30, 2026.
- Completion requires a majority of Pacira shares tendered; the offer is open for 10 business days, and the merger agreement's outside date is April 8, 2027.
- Pacira would pay Viatris a $62 million termination fee under specified circumstances, including a Superior Offer.
Read the filing on SEC.gov ↗
Aug 6, 7:56 AM ET
Viatris reported second-quarter 2026 results with total revenues of $3.8 billion, up 5% on a reported basis, and adjusted EBITDA of $1.2 billion, up 10%. A U.S. GAAP net loss of $119 million was driven mainly by a non-cash charge of $177.8 million tied to the planned sale of Tyrvaya product rights, and the company raised the midpoints of its 2026 guidance for all metrics.
- Total revenues $3.8 billion, up 5% reported and 3.5% operationally versus second-quarter 2025; adjusted EPS $0.69, up 11% reported
- U.S. GAAP net loss $119 million, or $(0.10) per share, versus a net loss of $5 million a year earlier, mainly from a $177.8 million non-cash Tyrvaya charge
- 2026 guidance midpoints raised: total revenues to $14.75 billion from $14.70 billion, adjusted EBITDA to $4.4 billion from $4.3 billion, adjusted EPS to $2.52 from $2.40
- Returned approximately $550 million to shareholders through August 5, 2026, including about $270 million in share repurchases; about $730 million remains under the buyback program
Read the filing on SEC.gov ↗
Jul 1, 4:20 PM ET
Viatris entered into an amended and restated term loan credit agreement on July 1, 2026, providing a ¥40 billion senior unsecured term loan facility with Mizuho Bank, Ltd. as administrative agent. The filing says proceeds will be used in part to repay the prior ¥40 billion unsecured term loan dated July 1, 2021, so the facility replaces existing debt of the same stated amount rather than adding a new borrowing of that size.
- Facility amount is ¥40 billion, the same principal as the prior term loan dated July 1, 2021, which the proceeds are partly used to repay.
- Interest is set at the TIBO Rate plus 1.10% per annum initially, with the margin able to change based on Viatris's credit ratings from S&P Global Ratings, Moody's and Fitch.
- Borrowings are due three years from the July 1, 2026 Closing Date and include a leverage ratio covenant of no greater than 3.75 to 1.00 at each fiscal quarter end.
- Mylan Inc., Utah Acquisition Sub Inc. and Mylan II B.V. guarantee the facility as of the Closing Date.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.